WallStreetZenWallStreetZen

NASDAQ: UTHR
United Therapeutics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for UTHR

Based on 7 analysts offering 12 month price targets for United Therapeutics Corp

Min Forecast
$435.00-20.14%
Avg Forecast
$574.86+5.53%
Max Forecast
$705.00+29.43%

Should I buy or sell UTHR stock?

Based on 7 analysts offering ratings for United Therapeutics Corp.

Buy
Strong Buy
2 analysts 28.57%
Buy
3 analysts 42.86%
Hold
2 analysts 28.57%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although UTHR's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates UTHR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their UTHR stock forecasts and price targets.

UTHR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-05
lockedlocked$00.00+00.00%2026-02-26
lockedlocked$00.00+00.00%2026-02-26
lockedlocked$00.00+00.00%2026-02-26
lockedlocked$00.00+00.00%2026-02-26
Wells Fargo
Top 35%
66
HoldMaintains$466.00-14.45%2026-02-26
Morgan Stanley
Top 6%
95
HoldMaintains$435.00-20.14%2025-10-10

1 of 1

Forecast return on equity

Is UTHR forecast to generate an efficient return?

Company
26.79%
Industry
66.83%
Market
179.76%
UTHR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is UTHR forecast to generate an efficient return on assets?

Company
24.13%
Industry
31.7%
UTHR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

UTHR earnings per share forecast

What is UTHR's earnings per share in the next 3 years based on estimates from 18 analysts?

Avg 1 year Forecast
$29.87-0.87%
Avg 2 year Forecast
$33.42+10.91%
Avg 3 year Forecast
$36.86+22.35%
UTHR's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

UTHR revenue forecast

What is UTHR's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$3.4B+7.77%
Avg 2 year Forecast
$3.8B+19.74%
Avg 3 year Forecast
$4.2B+33.41%
UTHR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

UTHR earnings growth forecast

How is UTHR forecast to perform vs Biotechnology companies and vs the US market?

Company
6.98%
Industry
11.97%
Market
36.16%
UTHR's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
UTHR's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
UTHR's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

UTHR revenue growth forecast

How is UTHR forecast to perform vs Biotechnology companies and vs the US market?

Company
9.98%
Industry
37.61%
Market
13.54%
UTHR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
UTHR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

UTHR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UTHR$544.71$574.86+5.53%Buy
MRNA$55.97$32.00-42.83%Hold
BNTX$90.84$130.50+43.66%Buy
ROIV$29.58$27.56-6.82%Strong Buy
RPRX$46.69$47.75+2.27%Strong Buy
View Top Biotech Stocks

United Therapeutics Stock Forecast FAQ

Is United Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: UTHR) stock is to Buy UTHR stock.

Out of 7 analysts, 2 (28.57%) are recommending UTHR as a Strong Buy, 3 (42.86%) are recommending UTHR as a Buy, 2 (28.57%) are recommending UTHR as a Hold, 0 (0%) are recommending UTHR as a Sell, and 0 (0%) are recommending UTHR as a Strong Sell.

If you're new to stock investing, here's how to buy United Therapeutics stock.

What is UTHR's earnings growth forecast for 2026-2028?

(NASDAQ: UTHR) United Therapeutics's forecast annual earnings growth rate of 6.98% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.16%.

United Therapeutics's earnings in 2026 is $1,334,700,000.On average, 18 Wall Street analysts forecast UTHR's earnings for 2026 to be $1,309,058,474, with the lowest UTHR earnings forecast at $1,104,273,611, and the highest UTHR earnings forecast at $1,592,259,832. On average, 17 Wall Street analysts forecast UTHR's earnings for 2027 to be $1,464,550,338, with the lowest UTHR earnings forecast at $996,895,780, and the highest UTHR earnings forecast at $1,769,893,444.

In 2028, UTHR is forecast to generate $1,615,628,755 in earnings, with the lowest earnings forecast at $977,567,771 and the highest earnings forecast at $2,224,101,668.

What is UTHR's revenue growth forecast for 2026-2028?

(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 9.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.

United Therapeutics's revenue in 2026 is $3,182,700,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $150,328,962,980, with the lowest UTHR revenue forecast at $135,734,343,542, and the highest UTHR revenue forecast at $160,759,952,248. On average, 17 Wall Street analysts forecast UTHR's revenue for 2027 to be $167,027,311,346, with the lowest UTHR revenue forecast at $138,451,660,074, and the highest UTHR revenue forecast at $197,619,036,174.

In 2028, UTHR is forecast to generate $186,092,354,756 in revenue, with the lowest revenue forecast at $140,774,527,432 and the highest revenue forecast at $230,445,972,988.

What is UTHR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: UTHR) forecast ROA is 24.13%, which is lower than the forecast US Biotechnology industry average of 31.7%.

What is UTHR's Price Target?

According to 7 Wall Street analysts that have issued a 1 year UTHR price target, the average UTHR price target is $574.86, with the highest UTHR stock price forecast at $705.00 and the lowest UTHR stock price forecast at $435.00.

On average, Wall Street analysts predict that United Therapeutics's share price could reach $574.86 by Mar 5, 2027. The average United Therapeutics stock price prediction forecasts a potential upside of 5.53% from the current UTHR share price of $544.71.

What is UTHR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: UTHR) United Therapeutics's current Earnings Per Share (EPS) is $30.13. On average, analysts forecast that UTHR's EPS will be $29.87 for 2026, with the lowest EPS forecast at $25.20, and the highest EPS forecast at $36.33. On average, analysts forecast that UTHR's EPS will be $33.42 for 2027, with the lowest EPS forecast at $22.75, and the highest EPS forecast at $40.38. In 2028, UTHR's EPS is forecast to hit $36.86 (min: $22.30, max: $50.75).

What is UTHR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: UTHR) forecast ROE is 26.79%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.